Tagitanlimab

DRUG4 trials

Sponsors

West China Hospital, Tianjin Medical University Second Hospital, Peking Union Medical College Hospital

Conditions

ER+HER2- Breast CancerProstate Adenocarcinoma With Neuroendocrine DifferentiationProstate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantRecurrent or Metastatic MSI-H/dMMR Gynecological MalignanciesResectable Head and Neck Squamous Cell Carcinoma

Phase 2

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Not yet recruitingNCT07109284

West China HospitalER+HER2- Breast Cancer

Start: 2025-09-30End: 2030-12-31Target: 55Updated: 2025-08-07

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

RecruitingNCT07179783

Tianjin Medical University Second HospitalProstate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation

Start: 2025-09-22End: 2027-07-31Target: 28Updated: 2025-09-18

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

RecruitingNCT07492914

West China HospitalResectable Head and Neck Squamous Cell Carcinoma

Start: 2026-05-11End: 2031-03-31Target: 30Updated: 2026-05-13

SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies

Not yet recruitingNCT07738757

Peking Union Medical College HospitalRecurrent or Metastatic MSI-H/dMMR Gynecological Malignancies

Start: 2026-09-01End: 2029-12-30Target: 80Updated: 2026-07-31